Dia-B Tech identifies effective ISF402, updates patent11:58,...

Dia-B Tech identifies effective ISF402, updates patent
11:58, Tuesday, 6 June 2006

Sydney - Tuesday - June 6: (RWE Aust Business News) - Melbourne
biotechnology group Dia-B Tech Ltd's (ASX:DIA) research has shown that
its patented ISF402 compound, when combined with insulin, will reduce
blood glucose levels.
The research has been conducted at Monash University.
Synthetically produced ISF402, comprising four amino acids, also
has a quicker action time in the body than naturally produced ISF,
chairman Michael Wooldridge said.
"The mechanisms of action of the ISF402 drug are now mapped," he
said.
"The provisional patent applications covering these discoveries
have been revised and updated to reflect recent findings.
"ISF402 is a natural hormone and has novel mechanisms of action."
Dia-B research into the ISF402 drug is focused on producing a
drug that can be taken orally with no side effects.
If successful, ISF402 will be marketed as a glucose reducing oral
drug targeting type 2 diabetes sufferers.
ISF402 breaks down insulin clusters by removing zinc from the
insulin, and assists the insulin receptors of the body to respond better
to remove glucose from the blood stream.
The company believes these recent findings are both a
confirmation and enhancement of its major discoveries originally
provisionally patented in 2005.
Dr Wooldridge said Dia-B researchers now know where ISF
comes from and how ISF works.
Dia-B shares were up 0.5 to 10.5c.
ENDS

Copyright © 2006 RWE Australian Business News. All rights reserved.